Novanta

Organic demand from medical, life-science and advanced-industrial OEMs will continue to underpin positive revenue growth for Novanta. If OEM programs remain steady, revenue growth provides the base for margin expansion and valuation upside; if OEM demand declines, growth (and the ability to leverage fixed costs) will falter.

Stable ~44% gross margins reflect differentiated, engineered products and pricing power rather than commoditized components, and that structural margin should persist absent new low‑cost competition or customer price concessions. Sustained high gross margins create the room to fund R&D, SG&A and acquisitions while still producing attractive operating margins and cash flow; loss of gross margin would force either lower profits or cutbacks in investment.

Operating margin expansion is not automatic — SG&A, integration/amortization or other operating costs can negate revenue gains, as evidenced in 2025 when operating income fell despite higher revenue. Even with durable revenue and healthy gross margin, failure to control operating expenses or realize synergies will prevent EPS and free cash flow upside, undermining the valuation.

Novanta's strong reported cash balance gives management optionality for M&A or buybacks, but consistent value requires operating cash flow to normalize — otherwise the cash stockpile may reflect one‑time financing or working‑capital moves rather than sustainably generated cash. A large cash balance can be used for accretive acquisitions or shareholder returns to re-rate the stock, but if operating cash flow remains weak the balance is less durable and may not support sustained capital deployment.

EPS recovery will require either margin improvement or share count reduction; absent those, EPS will remain pressured even if revenue grows. Investors care about per‑share earnings — revenue growth that is offset by dilution, lower operating income, or poor cash conversion will not produce shareholder returns.